Dynorphin A Inhibits Insulin Secretion Through Opioid Receptor–Dependent Modulation of β-Cell Ca2+ Dynamics
Diabetes · 2026
DOI: 10.2337/db26-0224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2026. Verfasst von Miranda Movahed und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Miller School of Medicine, University of Miami, Miami, FL. Hauptthemen laut MEDLINE: Dynorphins, Insulin-Secreting Cells, Insulin, Calcium. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Abstract (Originalsprache)
Opioids are classically associated with pain and reward; however, endogenous opioid peptides and their receptors are also expressed in pancreatic islets, where their physiologic role remains unclear. Building on evidence indicating that β-cells corelease dynorphin A with insulin, we show that applied dynorphin A inhibits insulin secretion during glucose stimulation. Dynorphin A dose-dependently suppresses glucose-stimulated insulin secretion in mouse and human islets while preserving insulin content and β-cell viability. Under dynamic perifusion, dynorphin A attenuates both first- and second-phase insulin release. Mechanistically, dynorphin A slows glucose-stimulated β-cell Ca2+ oscillations in pancreatic slices, reducing oscillatory frequency while prolonging individual Ca2+ events. Notably, the receptor requirements for the inhibitory response to applied dynorphin A differ across species; μ-opioid receptor blockade or β-cell–specific deletion abolishes inhibition in mouse islets, whereas δ-opioid receptor antagonism prevents dynorphin A–mediated inhibition in human islets. These findings define the opioid receptor mechanisms underlying the inhibitory response to applied dynorphin A and reveal species-dependent receptor involvement in mouse and human islets. Article Highlights The role of endogenous opioid signaling within pancreatic islets remains poorly defined. We investigated whether dynorphin A regulates insulin secretion and characterized the receptor requirements for the acute response to applied dynorphin A in mouse and human islets. Applied dynorphin A suppressed glucose-stimulated insulin secretion by remodeling β-cell Ca2+ oscillations through an opioid receptor–dependent, Na+/K+-ATPase–associated pathway. This response required μ-opioid receptors in mouse β-cells and was pharmacologically consistent with δ-opioid receptor involvement in human islets, defining species-dependent receptor mechanisms for the acute response to dynorphin A.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Miller School of Medicine, University of Miami, Miami, FL.
- Diabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL.
ORCID-Profile: Manuel Blandino-Rosano
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Zitieren
APA
Movahed, M., Gomareli, M., Louzada, R. A., & Blandino-Rosano, M. (2026). Dynorphin A Inhibits Insulin Secretion Through Opioid Receptor–Dependent Modulation of β-Cell Ca2+ Dynamics. Diabetes. https://doi.org/10.2337/db26-0224
Vancouver
Movahed M, Gomareli M, Louzada RA, Blandino-Rosano M. Dynorphin A Inhibits Insulin Secretion Through Opioid Receptor–Dependent Modulation of β-Cell Ca2+ Dynamics. Diabetes. 2026. doi:10.2337/db26-0224
BibTeX
@article{Movahed2026,
author = {Movahed, Miranda and Gomareli, Mariam and Louzada, Ruy A and Blandino-Rosano, Manuel},
title = {Dynorphin A Inhibits Insulin Secretion Through Opioid Receptor–Dependent Modulation of β-Cell Ca2+ Dynamics},
journal = {Diabetes},
year = {2026},
doi = {10.2337/db26-0224}
}
EUVIMED